Inclusion Criteria:

          -  The patient has newly-diagnosed, biopsy proven squamous cell carcinoma of Stage I-IV
             (T1-3, N0-2b) of the oropharynx.

          -  The patient's tumor is HPV positive by PCR or ISH assay of tumor biopsy.

          -  The patient is able/eligible to undergo treatment with transoral robotic surgery
             (TORS) with or without neck dissection and with or without adjuvant radiation therapy
             or chemoradiation.

          -  The patient is able to understand and give informed consent.

          -  The patient is at least 18 years old.

          -  The patient's ECOG performance status is </= 2.

        Exclusion Criteria:

          -  The patient has had prior head and neck squamous cell carcinoma (HNSCC), with the
             exception of superficial cutaneous basal cell or squamous cell carcinomas.

          -  The patient has active cancer in another part of the body, with the exception of
             superficial cutaneous basal cell or squamous cell carcinomas

          -  If a cancer survivor, the disease free interval is less than 3 years, with the
             exception of superficial cutaneous basal cell or squamous cell carcinomas.

          -  If a cancer survivor the patient received prior systemic chemotherapy or radiotherapy

          -  If prior standard-of-care pre-treatment biopsy is inadequate for analysis by
             immunohistochemistry, and the patient is unwilling to undergo an additional biopsy
             procedure.

          -  The patient is a prisoner.

          -  The patient has a psychiatric illness or developmental delay which would interfere
             with understanding of the study and provision of informed consent.

          -  The patient has previously received definitive surgical, radiation, or chemoradiation
             treatment for HNSCC.

          -  The patient has a history of HIV or other known cause of immunosuppression, or is
             actively taking immunosuppressive medications due to organ transplantation, rheumatoid
             disease, or other medical conditions.

          -  Patient is allergic to naproxen or Ibuprofen.

          -  The patient has a history of liver disease.

          -  The patient has a contraindication (e.g. sensitivity/allergy) to both
             trimethoprim/sulfamethoxazole and ampicillin.

          -  The patient has implanted medical device(s) that pose a high risk for colonization
             and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves,
             pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous
             implant(s)). NOTE: More common devices and prosthetics which include arterial and
             venous stents, dental and breast implants and venous access devices (e.g. Port-a-Cath
             or Mediport) are permitted.

          -  Patients who are receiving or may receive future treatment with PI3K or TNFα
             inhibitors.

          -  Patients who have undergone a major surgery, including surgery for a new artificial
             implant and/or device, within 6 weeks prior to the initiation of ADXS11-001 treatment.
             Sponsor must be consulted prior to enrolling subjects on the study who recently had a
             major surgery or have new artificial implant, and/or devices.

          -  Patients who have a history of listeriosis or prior ADXS11-001 therapy.

          -  Patients with a known allergy to any component of the study treatment formulations.

          -  Pregnancy. The effects of this vaccine on the developing human fetus are unknown. For
             this reason women of child-bearing potential and men must use two forms of
             contraception (i.e., barrier contraception and one other method of contraception) at
             least 4 weeks prior to study entry, for the duration of study participation, Should a
             woman become pregnant or suspect she is pregnant while participating in this study,
             she should inform her treating physician immediately.